MedTrace Logo

sST2 Biomarker Level in Acute/Chronic Coronary Syndrome After Revascularization

NCT05686057 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-01-17

No results posted yet for this study

Summary

The role of soluble circulating suppression of tumorigenicity 2 biomarker (sST2) in the ischemic heart disease patient is a debatable point. Therefore the aims of this study are to assess the plasma level of sST2 in ischemic heart disease patients versus non-ischemic ones, the acute changes in its level after percutaneous coronary intervention (PCI) and its relation to the severity of ischemia.

Conditions

Interventions

DEVICE

percutanous coronary angiography with stenting

Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.

Sponsors & Collaborators

  • South Valley University

    collaborator OTHER

  • Assiut University

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686057 on ClinicalTrials.gov